kapitonragomo.blogspot.com
The trial, called ADVANCE, will determinre the efficacy and safetyof Biogen’s drug called PEGylated interferon beta-1a, in reducintg relapse rates in patients with multiple sclerosis The global study will enrol l more than 1,200 patients with RMS between the ages of 18 and 55. The study’s goal is to determine whether the drug reduces the annualizeds relapse rate in patients with RMS at one The study will alsoexamine if, over time, the potentiall treatment can slow disease progression and lead to a decreasse in the number of a certaij kind of brain lesions commonly seen in MS The treatment is a combination of Interferon beta-1a, whichh has been used successfully to treat MS for more than 10 and PEGylation, which can extend the amoun of time a drug remains in a patient’s system.
If the trial is successful, the treatment has the potential to reduce the frequency of treatmengt injections and provide patients with an effective and more convenientgdosing option. Biogen’s (NASDAQ: BIIB) stock was tradiny at in $49.33 in morning trading on Monday, down from the previoud close of $51.67.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment